Dupilumab Treatment for Asthma: On the Road to a New Horizon Beyond Ethnic Differences?
Open Access
- 1 January 2022
- journal article
- editorial
- Published by The Korean Academy of Asthma, Allergy and Clinical Immunology and The Korean Academy of Pediatric Al in Allergy, Asthma & Immunology Research
- Vol. 14 (2) , 147-150
Abstract
Lee YW, et al. Allergy Asthma Immunol Res. 2022 Mar;14(2):147-150. https://doi.org/10.4168/aair.2022.14.2.147Keywords
Funding Information
- Inha University Hospital
This publication has 14 references indexed in Scilit:
- Dupilumab efficacy and safety in Japanese patients with uncontrolled, moderate-to-severe asthma in the phase 3 LIBERTY ASTHMA QUEST studyAllergology International, 2020
- Effectiveness and safety of dupilumab for the treatment of severe asthma in a real‐life French multi‐centre adult cohortClinical & Experimental Allergy, 2020
- Evaluation and Management of Difficult-to-Treat and Severe Asthma: An Expert Opinion From the Korean Academy of Asthma, Allergy and Clinical Immunology, the Working Group on Severe AsthmaAllergy, Asthma & Immunology Research, 2020
- Asthma biologicsAnnals of Allergy, Asthma & Immunology, 2020
- Omalizumab effectiveness in asthma-COPD overlap: Post hoc analysis of PROSPEROJournal of Allergy and Clinical Immunology, 2019
- Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled AsthmaNew England Journal of Medicine, 2018
- Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe AsthmaNew England Journal of Medicine, 2018
- Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary DiseaseNew England Journal of Medicine, 2017
- Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trialThe Lancet, 2016
- Dupilumab in Persistent Asthma with Elevated Eosinophil LevelsNew England Journal of Medicine, 2013